Format

Send to

Choose Destination
CNS Oncol. 2015;4(3):131-5. doi: 10.2217/cns.15.3. Epub 2015 Apr 23.

Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.

Author information

1
Department of Neurology, Johns Hopkins Hospital, David H. Koch Cancer Research Bldg II, 1550 Orleans Street, Room 1M16, Baltimore, MD 21287, USA.

Abstract

Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.

KEYWORDS:

CNS lymphoma; indolent lymphoma; intrathecal rituximab; low-grade lymphoma

PMID:
25905905
PMCID:
PMC4778415
DOI:
10.2217/cns.15.3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center